vTv Therapeutics Inc. (VTVT) is a pharmaceutical company with 7 drug candidates currently in different clinical stages. The programs are mainly focused on Alzheimer’s disease, diabetes, and inflammation. However, its most promising candidate, azeliragon, just failed Phase 3 trial for its intended co-primary endpoints. The company is now planning to conduct further clinical studies. Nevertheless, it is running out of cash and the expenses needed for additional trials would be a big problem for the company at the moment. It is unclear, how vTv will fund its operations in the future, and one big